How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy
Max-Joseph Grimm
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Search for more papers by this authorGesine Respondek MD
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Search for more papers by this authorMaria Stamelou MD
Second Department of Neurology, Attikon University Hospital, University of Athens, Athens, Greece
Search for more papers by this authorThomas Arzberger MD
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany
Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
Search for more papers by this authorLeslie Ferguson MD
Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Search for more papers by this authorEllen Gelpi MD
Neurological Tissue Bank and Neurology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CERCA, Barcelona, Catalonia, Spain
Institute of Neurology, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorArmin Giese MD
Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany
Search for more papers by this authorMurray Grossman MD
Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Search for more papers by this authorDavid J. Irwin MD
Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Search for more papers by this authorAlexander Pantelyat MD
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA
Search for more papers by this authorAlex Rajput MD
Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Search for more papers by this authorSigrun Roeber MD
Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany
Search for more papers by this authorJohn C. van Swieten MD
Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
Search for more papers by this authorClaire Troakes PhD, MSc
London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK
Search for more papers by this authorAngelo Antonini MD, PhD
Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, and Department of Neurosciences, Padova University, Padova, Italy
Search for more papers by this authorKailash P. Bhatia MD
Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, UK
Search for more papers by this authorCarlo Colosimo MD, FEAN
Department of Neurology, Santa Maria University Hospital of Terni, Terni, Italy
Search for more papers by this authorThilo van Eimeren MD
Departments of Nuclear Medicine and Neurology, University of Cologne, Cologne, Germany
Search for more papers by this authorJan Kassubek MD
Department of Neurology, University of Ulm, Ulm, Germany
Search for more papers by this authorJohannes Levin MD
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Department of Neurology, Ludwig-Maximilians-Universität, Munich, Germany
Search for more papers by this authorWassilios G. Meissner MD, PhD
Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand
Search for more papers by this authorChrister Nilsson MD
Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden
Search for more papers by this authorWolfgang H. Oertel MD
Department of Neurology, Philipps Universität, Marburg, Germany
Search for more papers by this authorInes Piot
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Search for more papers by this authorWerner Poewe MD
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
Search for more papers by this authorGregor K. Wenning MD, PhD
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
Search for more papers by this authorAdam Boxer MD, PhD
Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA
Search for more papers by this authorLawrence I. Golbe MD
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
Search for more papers by this authorKeith A. Josephs MD, MST, MSc
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorIrene Litvan MD
Department of Neurology, University of California, San Diego, California, USA
Search for more papers by this authorHuw R. Morris MD
Department of Clinical Neuroscience, UCL Institute of Neurology, Queen Square, London, UK
Search for more papers by this authorJennifer L. Whitwell PhD
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorYaroslau Compta MD
Parkinson's Disease & Movement Disorders Unit, Hospital Clínic/IDIBAPS/CIBERNED/European Reference Network for Rare Neurological Diseases (ERN-RND)/Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia, Spain
Search for more papers by this authorJean-Christophe Corvol MD, PhD
Sorbonne Université, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, ICM, Hôpital Pitié-Salpêtrière, Department of Neurology, Paris, France
Search for more papers by this authorAnthony E. Lang MD
The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada
Search for more papers by this authorJames B. Rowe MD
Department of Clinical Neurosciences and Cambridge Centre for Parkinson-Plus, Cambridge University, Cambridge, UK
Search for more papers by this authorCorresponding Author
Günter U. Höglinger MD
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Correspondence to: Prof. Dr. Günter U. Höglinger, Dept. of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Str. 17, D-81677 Munich, Germany. Phone: +49-89-4400-46464, Fax: +49-89-4400-46565; E-mail: [email protected].Search for more papers by this authorfor the Movement Disorder Society-endorsed PSP Study Group
Search for more papers by this authorMax-Joseph Grimm
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Search for more papers by this authorGesine Respondek MD
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Search for more papers by this authorMaria Stamelou MD
Second Department of Neurology, Attikon University Hospital, University of Athens, Athens, Greece
Search for more papers by this authorThomas Arzberger MD
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany
Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
Search for more papers by this authorLeslie Ferguson MD
Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Search for more papers by this authorEllen Gelpi MD
Neurological Tissue Bank and Neurology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CERCA, Barcelona, Catalonia, Spain
Institute of Neurology, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorArmin Giese MD
Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany
Search for more papers by this authorMurray Grossman MD
Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Search for more papers by this authorDavid J. Irwin MD
Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Search for more papers by this authorAlexander Pantelyat MD
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA
Search for more papers by this authorAlex Rajput MD
Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Search for more papers by this authorSigrun Roeber MD
Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany
Search for more papers by this authorJohn C. van Swieten MD
Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
Search for more papers by this authorClaire Troakes PhD, MSc
London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK
Search for more papers by this authorAngelo Antonini MD, PhD
Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, and Department of Neurosciences, Padova University, Padova, Italy
Search for more papers by this authorKailash P. Bhatia MD
Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, UK
Search for more papers by this authorCarlo Colosimo MD, FEAN
Department of Neurology, Santa Maria University Hospital of Terni, Terni, Italy
Search for more papers by this authorThilo van Eimeren MD
Departments of Nuclear Medicine and Neurology, University of Cologne, Cologne, Germany
Search for more papers by this authorJan Kassubek MD
Department of Neurology, University of Ulm, Ulm, Germany
Search for more papers by this authorJohannes Levin MD
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Department of Neurology, Ludwig-Maximilians-Universität, Munich, Germany
Search for more papers by this authorWassilios G. Meissner MD, PhD
Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand
Search for more papers by this authorChrister Nilsson MD
Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden
Search for more papers by this authorWolfgang H. Oertel MD
Department of Neurology, Philipps Universität, Marburg, Germany
Search for more papers by this authorInes Piot
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Search for more papers by this authorWerner Poewe MD
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
Search for more papers by this authorGregor K. Wenning MD, PhD
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
Search for more papers by this authorAdam Boxer MD, PhD
Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA
Search for more papers by this authorLawrence I. Golbe MD
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
Search for more papers by this authorKeith A. Josephs MD, MST, MSc
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorIrene Litvan MD
Department of Neurology, University of California, San Diego, California, USA
Search for more papers by this authorHuw R. Morris MD
Department of Clinical Neuroscience, UCL Institute of Neurology, Queen Square, London, UK
Search for more papers by this authorJennifer L. Whitwell PhD
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorYaroslau Compta MD
Parkinson's Disease & Movement Disorders Unit, Hospital Clínic/IDIBAPS/CIBERNED/European Reference Network for Rare Neurological Diseases (ERN-RND)/Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia, Spain
Search for more papers by this authorJean-Christophe Corvol MD, PhD
Sorbonne Université, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, ICM, Hôpital Pitié-Salpêtrière, Department of Neurology, Paris, France
Search for more papers by this authorAnthony E. Lang MD
The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada
Search for more papers by this authorJames B. Rowe MD
Department of Clinical Neurosciences and Cambridge Centre for Parkinson-Plus, Cambridge University, Cambridge, UK
Search for more papers by this authorCorresponding Author
Günter U. Höglinger MD
Department of Neurology, Technische Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Correspondence to: Prof. Dr. Günter U. Höglinger, Dept. of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Str. 17, D-81677 Munich, Germany. Phone: +49-89-4400-46464, Fax: +49-89-4400-46565; E-mail: [email protected].Search for more papers by this authorfor the Movement Disorder Society-endorsed PSP Study Group
Search for more papers by this authorRelevant conflicts of interest/financial disclosures: None.
Funding agencies: The project was supported by the Bischof Dr. Karl Golser Stiftung, CurePSP, Deutsche Forschungsgemeinschaft (DFG, HO 2402/11-1), German Center for Neurodegenerative Diseases e.V. (DZNE), German PSP Gesellschaft, Tau Consortium, UK PSP Association, and the International Parkinson & Movement Disorder Society.
Abstract
Background
The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them.
Methods
We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations.
Results
Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1.
Conclusions
The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society
References
- 1Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-359.
- 2Kovacs GG. Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 2015; 41: 3-23.
- 3Respondek G, Kurz C, Arzberger T, et al, for the Movement Disorder Society-endorsed PSP Study Group. Which ante-mortem features predict progressive supranuclear palsy? Mov Disord 2017; 32(7): 995-1005.
- 4Höglinger GU, Respondek G, Stamelou M, et al, for the Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy — the Movement Disorder Society Criteria. Mov Disord 2017; 32(6): 853-864.
- 5Ali F, Martin P, Botha H, et al. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Move Disord 2019; doi: https://doi.org/10.1002/mds.27619.
- 6Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29: 1758-1766.
- 7Whitwell JL, Höglinger GU, Antonini A, et al, Movement Disorder Society-endorsed PSP Study Group. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 2017; 32(7): 955-971.